| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Stocks Mutual Funds > Going Global through Mutual Funds |
|
Top Articles - Going Global through Mutual Funds
There are more than 13500 different publicly traded companies in the world today, and there are ov According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product er 700 more companies expected to go public within a year. In addition, every major developed coun ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in try offers investors various bonds to invest in. All of this makes for a lot of different investme lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ts and plenty of choice. Investors can take advantage of this choice through a good global balance here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe d fund that invests in bonds and stocks or a global equity fund that invests in stocks all around d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro the world. A global equity fund invests in stock markets around the world. These funds will have ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc portion of their investments invested in North America. Europe, and Asia. Some of these funds wil easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi l own hundreds of securities in order to participate in the growth prospects of many firms while d nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically iversifying the risk associated with investing in different companies. A good global equity fund w and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ll be a foundation for a well-diversified mutual fund portfolio for almost any investor. Investors ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi could consider including the AGF International Value Fund, the BPI Global Equity Fund, or the Fid ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a elity International Portfolio Fund in their portfolios. A global balanced fund is a fund that inv dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod sts in both stock and bond markets around the world. These funds will also always have a portion o cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin f their investments invested in stock and bond markets located in North America, Europe, and Asia. tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen They are more conservative than global equity funds because they invest in a combination of stock t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel and bonds, which affect the fund's performance. Over the long term these funds will provide a low ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust er rate of return for investors but they will also exhibit a lot less risk than a global equity fu y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products nd. They exhibit less risk because bonds are less volatile than stocks; they do not decline in val . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de e to the same magnitude or at the same time as global equity funds. A conservative investor should elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip find a good global balanced fund that will serve as a good foundation for a diversified portfolio tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Four Common Sense Tips for the Telephone Interview Shifting Preferences For Office Furniture Is it True You Can Earn Great Cash and Win Prizes with Paid Surveys
|